HC Wainwright Issues Pessimistic Forecast for Vigil Neuroscience (NASDAQ:VIGL) Stock Price

Vigil Neuroscience (NASDAQ:VIGL) had its price objective lowered by HC Wainwright from $17.00 to $14.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other brokerages also recently weighed in on VIGL. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, William Blair initiated coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Price Performance

Shares of Vigil Neuroscience stock opened at $2.02 on Friday. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06. The company has a market capitalization of $82.58 million, a P/E ratio of -0.98 and a beta of 1.82. The business has a 50 day moving average price of $2.34 and a 200 day moving average price of $2.79.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08). As a group, research analysts expect that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several institutional investors have recently made changes to their positions in VIGL. Walleye Capital LLC grew its stake in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after buying an additional 92,217 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience during the 3rd quarter valued at $442,000. Point72 Asset Management L.P. grew its stake in shares of Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after buying an additional 115,000 shares during the period. Geode Capital Management LLC grew its stake in shares of Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the period. Finally, abrdn plc grew its stake in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.